Investorideas.com

Call 800 665 0411 to learn about our services

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS


 


BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology, telemedicine, Covid-19

Like Biotech Stocks? View our Biotech Stocks Directory    Get News Alerts on Biotech Stocks


Featured Biotech stocks - Feature Your Company & Product Here

Biotech News

Co. Uses RNA Editing as Treatment for Rare Disease
October 4, 2022 (Investorideas.com Newswire) The firm plans to advance its alpha-1 antitrypsin deficiency program into the clinic next year, noted an H.C. Wainwright & Co. report.

Biotech Investor Stock News: NurExone (TSXV: NRX) Announces Scientific Survey Results of Proprietary Exosome-based Technology
Calgary, Alberta - October 4, 2022 (Newsfile Corp.) (Investorideas.com Newswire) NurExone Biologic Inc. (TSXV: NRX) (FSE: J90), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, announced today results from a controlled survey in the Company's lab showing the effectiveness of the Company's proprietary small interfering RNA in inhibiting the expression of the phosphatase and tensin homolog.

Interim Results From Phase 2b Trial Are 'Encouraging'
October 3, 2022 (Investorideas.com Newswire) Data show the biotech's compound had a positive effect on several noninvasive measures, noted a ROTH Capital Partners report.

Biopharma Asks for Emergent Use in US of New COVID Drug
September 30, 2022 (Investorideas.com Newswire) The requested approval is specifically for critically ill patients, a population for which the U.S. Food and Drug Administration granted the therapeutic fast track status

US Biotech Firm Keeps Growing Revenue
September 27, 2022 (Investorideas.com Newswire) Revenue last quarter was strong, and management expects to increase revenue 20% this fiscal year, noted a ROTH Capital Partners report.

Analyst Says Buy Before Biotech Co.'s Clinical Trials
September 26, 2022 (Investorideas.com Newswire) Argenx SE has "several upcoming catalysts," noted a Wedbush report. Argenx SE's (ARGX:NASDAQ) drug for generalized myasthenia gravis

Co.'s Clinical Program in HPV+ Cancers Gives It a Buy Rating
September 26, 2022 (Investorideas.com Newswire) To fund continued development of its lead immunotherapy candidate, the U.S.-based biopharma recently completed a $35 million debt financing agreement

Telemedicine Co. Says It's Set To Thrive in Post-Pandemic World
September 22, 2022 (Investorideas.com Newswire) The pandemic changed the way many people get their basic healthcare, giving a big opening to telemedicine companies like Reliq Health Technologies Inc.

Important Catalyst Expected Soon for Cancer Drug Co.
September 21, 2022 (Investorideas.com Newswire) The biopharma should announce initial clinical trial data on its lead small molecule candidate by year-end, noted a Wedbush report.

Dermatology Co.'s Target Price Much Larger Than Current
September 21, 2022 (Investorideas.com Newswire) The biopharma's strategic marketing campaign "should continue growing U.S. sales to current and new customers,"

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Other Ideas - Guest Posts and / or sponsored financial content

Learn how to be published on our site: Buy a guest post on Investorideas.com

Biotech News from Newsfile

Marvel Biosciences Highlights Recent Research on the Serotonin Theory of Depression
Calgary, Alberta--(Newsfile Corp. - October 4, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) (the "Company" or "Marvel") highlights recent a meta-analysis which re-evaluated the strength of the link between serotonin levels and depression. According to the study published in Nature Molecular Psychiatry on July 20, 2022 1, despite the influence of the serotonin theory of depression, there was no comprehensive review of the scientific literature undertaken, despite the various known facts of the patients taking...

Hemostemix Announces Exploring Clinical Trial Financing Alternatives
Calgary, Alberta--(Newsfile Corp. - October 4, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce that the Company has commenced discussions with pharmaceutical companies to explore potential clinical trial financing alternatives for its lead product ACP-01 (the "Clinical Trial Financing Alternatives"), after retaining experts in the field of biotech business development who have significant experience completing deals on behalf of pharmaceutical companies with promising companies...

PharmaDrug Advances Programs in Oncology and Infectious Disease Through Completion of cGMP Drug Substance Manufacturing
Completes clinical trial-scale production of cGMP Cepharanthine-2HCL drug substanceOptimized manufacturing processes substantially increases drug product yield To initiate ICH-compliant stability, forced degradation and drug product manufacturing in support of IND filing and clinical requirementsToronto, Ontario--(Newsfile Corp. - October 4, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and other naturally-derived approved drugs, is pleased to announce that the...

Naturevan Expands Distribution to Asia
Toronto, Ontario--(Newsfile Corp. - October 3, 2022) - ScreenPro Security Inc. (CSE: SCRN) (OTCQB: SCRSF) ("ScreenPro" or the "Company") is pleased to announce that further to the news release on September 15, 2022, the Company's wholly-owned subsidiary, Naturevan Nutrition Ltd. ("Naturevan"), will further expand distribution of its products to Japan and South Korea.Management is currently working on distribution agreements in Asia which will allow the Company to expand supply to a larger audience and enter...

BioHarvest Sciences Inc. Reports Record Sales Results in Q3 2022 with Strong Momentum Building on All Fronts
VINIA® sales orders reached a record high of USD 1.71M representing 145% growth compared to Q3 2021 and 81% growth compared to Q2 2022Q3 Sales in the US delivered 3X the sales of Q2 2022 and crossed the USD 1 Million mark Strong sales momentum and increase in subscribers support guidance to achieve USD 5M-7M sales orders in in 2022, and cash flow positive in 2023Unique Cannabis composition (analysis performed by independent 3rd party certified...

Subscribe to Biotech News